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Human epididymal secretory protein E4 (HE4, also known as WAP four-disulphide core domain protein 2) is a new promising
biomarker for ovarian cancer but its specificity against ovarian endometriotic cysts is only superficially known. We, thus, analysed
serum HE4 concentrations together with a tumour marker CA125 in serum samples of women diagnosed with various types of
endometriosis, endometrial cancer or ovarian cancer, and in samples from healthy controls. The mean serum concentration of HE4
was significantly higher in serum samples of patients with both endometrial (99.2pM, Po0.001) and ovarian (1125.4pM, Po0.001)
cancer but not with ovarian endometriomas (46.0pM) or other types of endometriosis (45.5pM) as compared with healthy controls
(40.5pM). The serum CA125 concentrations were elevated in patients with ovarian cancer, advanced endometriosis with peritoneal
or deep lesions, or ovarian endometriomas, but not in the patients with endometrial cancer. The microarray results revealed that the
mRNA expression of the genes encoding HE4 and CA125 reflected the serum protein concentrations. Taken together, measuring
both HE4 and CA125 serum concentrations increases the accuracy of ovarian cancer diagnosis and provides valuable information to
discriminate ovarian tumours from ovarian endometriotic cysts.
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Endometriosis is one of the most common benign gynaeco-
logical conditions, it may affect up to 10% of women in
reproductive age. The typical symptoms caused by endo-
metriosis are pain and subfertility. Endometriosis is characterised
by the appearance of endometrial glands and stroma in ectopic
locations outside the uterine cavity. The lesions are typically
located on the peritoneum, in the ovaries or infiltered into the
organs within the abdominal cavity (Giudice and Kao, 2004).
There are several theories for the aetiology of endometriosis
and it has been suggested that the peritoneal lesions, deep
rectovaginal lesions, and ovarian endometriotic cysts called
endometriomas would be of different origin (Nisolle and Donnez,
1997).
Although transvaginal ultrasound examination is of value,
particularly in women with ovarian endometriomas, the diagnosis
of endometriosis typically requires laparoscopic verification. The
ultrasound is not a useful tool in the diagnostics of peritoneal
implants and adhesions or in staging of the disease. In addition,
neoplastic ovarian cysts can resemble endometriomas in ultra-
sound and, therefore, need to be carefully considered in the
differential diagnostics. Furthermore, endometriosis is shown to
increase the risk of certain subtypes of ovarian cancer, such as
endometrioid and clear-cell carcinomas (Nagle et al, 2008). There
are data indicating that 40% of endometrioid ovarian carcinomas
and 50% of clear-cell ovarian carcinomas are associated with
endometriosis (Sato et al, 2000). Both endometrioid and clear-cell
carcinomas are thought to arise, at least partly, from endo-
metriosis. Similar pathophysiological mechanisms may be in-
volved in the progression of endometriosis as well as in its
transformation into ovarian neoplasia (Ness, 2003).
Currently, CA125 antigen is the most commonly used biochem-
ical marker in ovarian cancer diagnostics. However, it is associated
with a high false-positive rate among women with benign
gynaecological conditions such as endometriosis (Markman,
1997). Furthermore, CA125 has very low sensitivity in identifying
patients with early-stage ovarian cancer (Terry et al, 2004). Thus,
to improve the specificity and sensitivity of ovarian cancer
diagnosis, the use of novel biomarkers such as HE4 (human
epididymal secretory protein E4; WAP four-disulphide core
domain protein 2, WFDC2) alone or in combination with CA125
has been intensively studied (Hellstro ¨m et al, 2003; Havrilesky
et al, 2008; Moore et al, 2008a).
In addition to diagnosis of ovarian cancer, CA125 can be used to
evaluate the efficacy of endometriosis therapy as well as the
recurrence of endometriosis. However, the lack of sensitivity and
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sspecificity of the biomarker has significantly hampered its use as a
diagnostic test (Mol et al, 1998; Kitawaki et al, 2005). On the other
hand, a panel of markers including CA125 has been suggested to
predict the presence of endometriosis in a subset of patients
(Seeber et al, 2008).
Human epididymal secretory protein E4 is a new serological
biomarker for diagnosis of ovarian cancer. As compared with the
markers used previously, it possesses increased sensitivity for
detecting ovarian cancer, especially the stage I disease (Havrilesky
et al,2 0 0 8 ;M o o r eet al, 2008a), whereas the HE4 encoding gene
WFDC2 is expressed particularly in serous and endometrioid ovarian
cancer (Drapkin et al, 2005; Galgano et al, 2006). However, it is shown
to be expressed also in some other types of tumours, for example lung
adenocarcinoma (Galgano et al, 2006). Its expression is also apparent
in normal endometrial glands and endometrial cancer (Drapkin et al,
2005; Galgano et al, 2006), but the expression in endometriotic lesions
including ovarian endometriomas is not known.
In the present study, we measured serum concentrations of HE4
and CA125 in 129 patients with endometriosis of whom 69 had
ovarian endometriomas. The data were compared with results
obtained in 16 patients with endometrial cancer, 14 with ovarian
cancer, and 66 healthy controls. The mRNA expression of genes
encoding HE4 and CA125, namely WFDC2 and MUC16, respec-
tively, was also analysed in the tissue specimens of various types of
endometriosis, ovarian cancer, endometrial cancer, and normal
endometrium.
PATIENTS AND METHODS
Patients
The patients were enrolled into the study in two Central Hospitals
and two University Central Hospitals in Finland between October
2005 and November 2007. A written informed consent was
required from all patients before sampling, and the study protocol
was approved by the joint ethics committee of Turku University
and Turku University Central Hospital, Turku, Finland.
The serum samples of women diagnosed with endometriosis
(Endo, n¼129), ovarian cancer (OvCa, n¼14), or endometrial
cancer (EmCa, n¼16) were included into the study, together with
66 samples collected from healthy controls (Ctrl). The serum
samples of patients with ovarian endometrioma (OvEndo, n¼69,
ASRM stage 3–4) were evaluated as a separate group in the
analysis. The diseases were diagnosed per operatively in laparo-
scopy or laparotomy and confirmed by histopathological evalua-
tion. Description of patients included in the study is presented in
Table 1. Patients with endometriosis were classified to stage 1–4
according to the revised American Society for Reproductive
Medicine (ASRM) criteria (1997). The patients with ovarian and
endometrial cancer were staged according to the FIGO guidelines
(Benedet et al, 2000). The 14 ovarian carcinomas included 7
serous, 3 mucinous, 2 clear-cell, 1 endometrioid, and 1 small-cell
carcinomas. Four of the ovarian cancers were local stage I cancers
and the remaining 10 were of advanced stage II–IV. All
endometrial carcinomas were endometrioid adenocarcinomas. In
14 patients the cancer was limited to the uterus (stage I–II),
whereas in 2 cases metastatic pelvic lymph nodes were present
(stage III). Control subjects (n¼66) were verified to be free from
endometriosis or ovarian cancer by laparoscopy during the tubal
sterilisation, and the possibility of endometrial cancer was
excluded by endometrial biopsy. The mean age of patients with
endometriosis, ovarian cancer, endometrial cancer, and healthy
controls was 31.8, 63.8, 60.5, and 38.5 years, respectively.
The gene expression of WFDC2 and MUC16, which encode the
HE4 and CA125 proteins, respectively, was evaluated in 149 non-
ovarian endometriotic lesions, 28 ovarian endometriotic cysts,
15 ovarian and 14 endometrium carcinomas, 64 individual
endometrium samples from patients with endometriosis, and 41
endometrium samples from healthy controls. Thirteen of the ovarian
carcinomas were serous, one was endometrioid and one undifferen-
tiated. All endometrial carcinomas were endometrioid adeno-
carcinomas. The tissue samples were collected during laparoscopic
or open surgery. Endometrial biopsies were collected using a sterile
Pipelle sampler (Pipelle de Cornier; Laboratoire CCD, Paris, France).
All tissue samples were snap-frozen and stored in liquid nitrogen.
Serum HE4 and CA125 analysis
Serum samples were collected just before surgery into non-
heparinised tubes and centrifuged for 15min at 3000r.p.m. (800g)
after keeping 30min at room temperature. The serum was stored at
 20 or  801C. Human epididymal secretory protein E4 and CA125
concentrations were analysed in serum samples by ELISA analysis
(Fujirebio Diagnostics Inc., Malvern, PA, USA) according to
manufacturer’s instructions.
Expression analysis
The gene expression levels of WFDC2 and MUC16 were studied
as part of our whole-genome microarray analysis. The total RNA
was isolated with Trizol reagent (Invitrogen, Carlsbad, CA, USA),
further purified with RNeasy columns (Qiagen, Valencia, CA, USA)
and DNase treated (RNase-free DNase Set (Qiagen) or DNase I
(Invitrogen)). The RNA concentrations were measured with
NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA,
USA) and RNA quality was controlled by Experion analysis
(Bio-Rad Laboratories, Hercules, CA, USA). All subsequent steps
of the microarray analysis were carried out at the Finnish DNA-
Microarray Centre utilising the Sentrix Human Illumina 6 V2
Expression BeadChips (Illumina, San Diego, CA, USA), which
contains over 47000 known genes, gene candidates, and splice
variants. RNA sample (300ng each) was used as template for
producing double-stranded cDNA, and then biotinylated cRNA
using the Illumina RNA TotalPrep Amplification Kit (Ambion Inc.,
Austin, TX, USA). The labelled cRNA was purified and hybridised
to the BeadChip at 551C for 16h following the Illumina Whole-
Genome Gene Expression Protocol for BeadStation. Hybridisation
was detected with Cyanine3-streptavidine (GE Healthcare, Little
Chalfont, UK) and the arrays were scanned with the Illumina
BeadArray Reader. Normalisation and statistical analyses of the
microarray data were performed using the statistical software R
package limma (http://www.R-project.org) or Sigma Stat 3.1 (SPSS
Inc., Chicago, IL, USA). The expression levels were analysed using
Table 1 Description of patients included in the analysis of serum HE4
and CA125
Classification (ASRM)/stage (FIGO)
Diagnosis n 1/I 2/II 3/III 4/VI
Healthy 66
Endometriosis all 129 16 17 33 63
Ovarian endometrioma 69 — — 24 45
Endometrial cancer 16 13 1 2 —
Ovarian cancer 14 41 7 2
Serous 7 — — 61
Mucinous 3 3 — — —
Clear cell 2 — 11 —
Endometrioid 1 1 — — —
Small cell 1 — — — 1
Total 225
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sthe probes ILMN_1706612 and ILMN_1799120 for WFDC2 and
ILMN_1736316 for MUC16.
Statistical analyses
The statistical analyses of serum HE4 and CA125 concentrations
alone and in combination were performed using Tukey’s multiple
comparisons of means with 95% family-wise confidence level.
The classification capability of the HE4 and CA125 markers,
alone and together, was assessed using the binary and multinomial
logistic regression models with leave-one-out cross-validation. In
the cross-validation each sample in turn was reserved for testing
whereas the others were used in the model building. The sensitivity
at 95% specificity and the proportion of correctly classified
samples (accuracy) was calculated for each cross-validated
regression model. Also, for each binary model, the receiver
operator characteristic curves were constructed and the area under
the curve was used to summarise the overall performance of the
regression model.
RESULTS
Serum HE4 and CA125 concentrations
The mean serum HE4 concentrations were similar and below the
70pM limit for elevated value (Moore et al, 2008a) in patients with
endometriosis (mean 45.5pM) and in healthy controls (40.5pM),
irrespective of the disease classification or the presence of ovarian
endometrioma (ASRM stage 1: 46.7pM; stage 2: 44.9pM; stage 3:
43.2pM; stage 4: 46.5pM; OvEndo: 46.0pM). However, in addition
to the highly increased HE4 concentration in patients with ovarian
cancer (1125.4pM), the HE4 serum concentration was significantly
elevated also in patients with endometrial cancer (99.2pM,
Po0.001). The levels of HE4 in different types of ovarian cancer
were highest in serous (2031.1pM, n¼7) carcinomas, whereas it
was clearly elevated also in clear-cell (397.6pM, n¼2) and muci-
nous (202.6pM, n¼3) carcinomas. The serum concentrations in
the different patient groups are presented in Table 2 and Figure 1.
The serum levels of CA125 were highest in patients with ovarian
cancer (mean 1117.1Uml
 1, Po0.001) but were also significantly
(Po0.001) elevated in patients with ovarian endometrioma
(44.3Uml
 1) and advanced non-ovarian endometriosis (ASRM
stage 4, 40.8Uml
 1) as compared with healthy controls (8.9Uml
 1).
These concentrations were also higher than the threshold value for
elevated CA125 result (35Uml
 1). The concentration increased with
increasing ASRM stage of endometriosis (Table 2). However, the
median concentration (33.7Uml
 1) in patients with endometrioma
is below the threshold value for elevated CA125 result. In sera of
patients with endometrial cancer the level of CA125 (22.0Uml
 1)
was also significantly (P¼0.029) higher than in healthy controls
even though clearly lower than the threshold value.
Table 2 Serum HE4 and CA125 concentrations in patients with endometriosis, endometrial, and ovarian cancer
HE4 (pM) CA125 (Uml
 1)
Diagnosis n Mean s.d. Median (range) P-value
a Mean s.d. Median (range) P-value
a
Controls 66 40.5 10.3 38.6 (27.0–80.7) — 8.9 6.2 6.7 (2.2–31.2) —
Endometriosis all 129 45.5 13.4 43.5 (15.2–111.0) — 35.8 36.0 25.3 (0.8–182.0) —
Stage 1 16 46.7 11.4 42.9 (35.1–80.9) 0.96192 15.6 9.8 11.5 (5.1–44.4) 0.34560
Stage 2 17 44.9 13.1 43.9 (28.7–72.0) 0.99718 21.4 18.4 14.8 (3.5–70.5) 0.09637
Stage 3 33 43.2 11.4 43.4 (15.2–68.0) — 25.1 22.7 14.8 (0.9–79.0) —
Stage 3 w/o OvEndo 9 43.9 10.1 43.8 (32.6–61.9) 0.99971 23.3 25.4 13.4 (2.6–79.0) 0.58802
Stage 4 63 46.5 15.0 44.0 (26.8–111.0) — 50.4 43.1 36.7 (0.8–182.0) —
Stage 4 w/o OvEndo 18 43.5 12.1 40.9 (27.4–64.5) 0.99973 40.8 30.9 32.1 (0.8–127.0) 0.00001
Ovarian endometriosis 69 46.0 14.9 44.0 (15.2–111.0) 0.89441 44.3 42.1 33.7 (0.9–182.0) 0.00000
Endometrial cancer 16 99.2 76.4 73.3 (26.5–330.5) 0.00001 22.0 23.0 15.5 (9.6–106.0) 0.02915
Ovarian cancer 14 1125.4 2670.0 268.3 (46.5–10250.0) 0.00000 1117.1 1971.0 240.0 (6.6–6890.0) 0.00000
0.00000
b 0.00000
b
Serous 7 2031.1 3669.1 562.5 (46.5–10250.0) — 1938.7 2588.7 341.0 (28.9–6890.0) —
Mucinous 3 202.6 189.7 113.0 (74.4–420.5) — 201.5 186.0 221.0 (6.6–377.0) —
Clear cell 2 397.6 477.2 397.6 (60.1–735.0) — 674.5 587.6 674.5 (259.0–1090.0) —
Endometrioid 1 70.0 — 70.0 — — 97.0 — 97.0 — —
Small cell 1 64.1 — 64.1 — — 17.8 — 17.8 — —
aTukey’s multiple comparisons of means, in comparison to the healthy controls.
bComparison to patients with ovarian endometriosis.
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Figure 1 Correlation between serum HE4 (pM) and CA125 (Uml
 1)
concentrations as ln-transformation in patients with ovarian endometriosis
(Ovarian endo, J), ovarian cancer (OvCa, K), endometrial cancer
(EmCa, m), and controls (ctrl, X). The broken lines show the threshold
values for positive diagnosis of CA125 (35Uml
 1) and HE4 (70pM,
according to Moore et al (2008a)).
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sSensitivities for the separation of the patient groups by HE4,
CA125, or their combination were calculated for each two-wise
comparison at specificity of 95%. To differentiate the patients with
ovarian cancer from healthy controls, the combination of CA125
and HE4 relative to CA125 or HE4 alone resulted in the highest
accuracy (96.3%) and sensitivity (92.9%; Table 3). Furthermore,
the combination had the highest accuracy (94.0%) and sensitivity
(78.6%) also for differential diagnosis of patients with ovarian
cancer from those with ovarian endometriosis. The combination
also differentiates ovarian endometriosis from healthy controls
almost as accurately as CA125 alone, even though HE4 alone is a
poor marker for endometriosis. Finally, the combination of HE4
and CA125 had the highest accuracy (81.9%) also in the three-wise
comparison between the ovarian cancer, ovarian endometriosis,
and healthy controls.
Expression of HE4 and CA125 encoding genes
The mRNA expression of WFDC2 (encoding HE4) and MUC16
(encoding CA125) in the tissue samples is shown in Table 4. The
expression in ovarian cancer was compared to that of ovarian
endometrioma, and the expression in endometrial cancer and non-
ovarian endometriotic lesions was compared with that of the
normal endometrium of healthy controls. The expression of
WFDC2 was significantly (Po0.05) higher in ovarian cancer
(median of log2 intensity value 9.25) than in the ovarian
endometrioma (6.73) with fold change (FC) of 5.7. However, the
1.9-fold higher expression in endometrial cancer (8.61) did not
reach significance when compared with healthy endometrium
(7.67). The expression data is, thus, in line with the differential
serum concentrations observed for HE4 in the different patient
groups and controls. In contrast, the mRNA expression of MUC16
was relatively stable in the various specimens, whereas the FC
between all comparisons was between 0.7 and 1.3.
DISCUSSION
HE4 is a novel serological marker used especially for ovarian
cancer diagnosis (Hellstro ¨m et al, 2003; Gagnon and Ye, 2008;
Hellstro ¨m and Hellstro ¨m, 2008; Moore et al, 2008a). Because of its
high sensitivity, it is useful also for detecting stage I ovarian cancer
(Havrilesky et al, 2008; Moore et al, 2008a). Furthermore, HE4 has
been suggested as a biomarker for the diagnosis of endometrial
cancer (Moore et al, 2008b). Currently, several biomarker panels
are being evaluated to increase the sensitivity and specificity of
ovarian cancer diagnosis. The combination of CA125 and HE4
with, or without, other biomarkers such as Glycodelin, Plau-R,
MUC-1, PAI-1 (Havrilesky et al, 2008), SMRP (Hellstro ¨m and
Hellstro ¨m, 2008; Moore et al, 2008a), CA72-4, and osteopontin
(Moore et al, 2008a) has been evaluated to improve ovarian
cancer diagnosis. The data suggest that by combining these
markers the predictive accuracy in ovarian malignancy is better
than by applying any of the markers alone. The panel of
biomarkers including HE4 has been evaluated also for monitoring
the recurrence of ovarian cancer (Havrilesky et al, 2008; Moore
et al, 2009).
In female tissues, HE4 immunoreactivity has been shown to be
highest in glandular epithelium of the genital tract, including
endocervical glands, endometrial glands, fallopian tubes, and
Bartholin’s glands (Drapkin et al, 2005; Galgano et al, 2006). In
contrast to the normal ovarian surface epithelium, which does not
express HE4, cortical inclusion cysts lined by metaplastic
Mu ¨llerian epithelium have been shown to express the protein
abundantly (Drapkin et al, 2005). The expression of HE4 protein in
ovarian tumours is highest in serous carcinomas but immuno-
staining has been detected also in the vast majority of ovarian
endometrioid and clear-cell carcinomas (Drapkin et al, 2005;
Galgano et al, 2006). In addition to ovarian carcinoma, some
pulmonary, endometrial, and breast adenocarcinomas have been
shown to express HE4 (Galgano et al, 2006). Although the protein
has been detected in both normal and malignant endometrium, the
expression of HE4 in the endometriotic lesions is only superficially
known. Recently, Moore et al (2008a) analysed HE4 and eight
other biomarkers in the sera of 166 patients with ovarian cancer
or with several other kinds of pelvic masses, of whom 29 had
endometriosis. They showed that the HE4 and CA125 concentra-
tions were the best combination of biomarkers to distinguish
Table 3 Tumour marker accuracy and sensitivity at 95% specificity for
ovarian cancer and ovarian endometriosis
Markers Accuracy (%) ROC-AUC (%) Sensitivity (%)
OvCa vs OvEndo
CA125+HE4 94.0 91.3 78.6
CA125 92.8 77.0 64.3
HE4 91.6 91.9 71.4
OvCa vs ctrl
CA125+HE4 96.3 91.1 92.9
CA125 96.3 91.7 78.6
HE4 93.8 95.5 78.6
OvEndo vs ctrl
CA125+HE4 82.2 86.8 62.3
CA125 83.0 87.7 60.9
HE4 60.7 60.5 5.8
OvCa vs OvEndo vs ctrl
CA125+HE4 81.9
CA125 81.2
HE4 59.7
OvCa¼ovarian cancer; OvEndo¼ovarian endometriosis.
Table 4 Expression of WFDC2 (HE4) and MUC16 (CA125) mRNA in tissue specimens of endometrium, non-ovarian and ovarian endometriosis,
endometrial cancer, and ovarian cancer as log2 intensity values
WFDC2 MUC16
Sample group N Median 25% 75% FC P-value
a Median 25% 75% FC P-value
a
E of healthy control 41 7.67 6.96 8.28 7.1 6.76 7.48
E of endo patient 64 7.75 7.17 8.28 1.1
b NS
b 7.21 6.86 7.63 1.1
b NS
b
Non-ovarian endo 149 7.03 6.65 7.44 0.6
b o0.05
b 6.62 6.48 6.84 0.7
b o0.05
b
Ovarian endo 28 6.73 6.45 7.13 6.49 6.37 6.65
EmCa 14 8.61 8.06 9.24 1.9
b NS 6.28 6.14 7.29 0.6
b o0.05
b
OvCa 15 9.25 8.36 10.04 5.7
c o0.05
c 6.86 6.66 7.74 1.3
c o0.05
c
E¼endometrium; EmCA¼endometrial cancer; endo¼endometriosis; OvCa¼ovarian cancer; NS¼not significant.
aDunn’s method.
bCompared to endometrium specimens
of healthy controls.
cCompared to ovarian endometriomas.
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However, the types of endometriosis lesions in these patients were
not described.
In agreement with other recent studies (Hellstro ¨m et al, 2003;
Gagnon and Ye, 2008; Hellstro ¨m and Hellstro ¨m, 2008; Moore et al,
2008a,b), we detected increased HE4 concentration in patients
with ovarian and endometrial cancer. The present data demon-
strate that neither the expression of HE4 encoding gene in the
endometriotic lesions nor serum HE4 concentration in the patients
with endometriosis with any types of endometriosis is increased. It
is of specific interest to note that HE4 is not increased even in
patients with ovarian endometriosis. In contrast, the serum level of
CA125 was increased in patients with advanced endometriosis and
ovarian endometriomas, as expected. It should be noted that
endometriosis is typically diagnosed at young adult age (25–35
years) and often disappears after menopause, whereas the
incidence of ovarian cancer increases in older women (highest
incidence at the age of 50–60 years). Interestingly, it has been
reported that the concentration of HE4 increases with age in
healthy postmenopausal woman whereas CA125 does not (Lowe
et al, 2008).
Thus, measuring both HE4 and CA125 together, rather than
either of them alone, provides a more accurate tool for differential
diagnosis of patients with ovarian cancer and ovarian endome-
triotic cysts from healthy subjects. It may also help clinicians in the
follow-up of patients suffering from advanced endometriosis when
considering the possibility of malignant transformation of the
lesions. Within the patients with ultrasound-detected ovarian
mass, the high serum HE4 with high CA125 would suggest
the presence of ovarian cancer whereas elevated CA125
without elevated HE4 would direct towards advanced or ovarian
endometrioma or other benign conditions. Furthermore, the
elevated serum HE4 concentration with normal CA125 concentra-
tion would suggest the presence of either ovarian or possibly other
type of cancer, for example endometrial cancer.
The greatest benefit of highly specific differentiation between
ovarian cancer and endometriosis may well be found in
identification of ovarian cancer in the early non-symptomatic
stage. A high proportion of ovarian cancers are diagnosed at an
advanced stage with a dismal survival rate. In contrast, the 5-year
survival rate for stage I disease with the malignancy confined to
the ovary is above 90%. This emphasises the importance of
detecting the ovarian cancers at their early stage to improve the
mortality rate.
In summary, the serum concentration of HE4, a novel
biomarker for ovarian cancer, was not increased in patients with
ovarian endometrioma or any other types of endometriosis,
whereas the serum CA125 concentration was increased in patients
with advanced endometriosis. The results, thus, suggest that the
serum HE4 concentration is a valuable marker to better
distinguishing patients with ovarian malignancies from those
suffering from the benign ovarian endometriotic cysts.
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